Roche launches Vabysmo® (faricimab), the first and only bispecific monoclonal antibody for the eye, to treat two leading causes of vision loss

Mumbai, March 07, 2024: Roche Pharma India marked its foray into the Ophthalmology space by launching Vabysmo® (faricimab) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DME are two leading causes of vision loss worldwide. Vabysmo® is the first and only dual-pathway-inhibitor that uniquely targets and inhibits two disease

Read more